This HTML5 document contains 78 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/wikipedia/
n8http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/mixture/
n10http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n21http://www.drugs.com/mtm/
n5http://linked.opendata.cz/resource/drugbank/patent/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n20http://www.rxlist.com/nesina-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/chebi/
n13http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06203
rdf:type
n3:Drug
n3:description
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
n3:dosage
n16:271B49DA-363D-11E5-9242-09173F13E4C5 n16:271B49D8-363D-11E5-9242-09173F13E4C5 n16:271B49DB-363D-11E5-9242-09173F13E4C5 n16:271B49D9-363D-11E5-9242-09173F13E4C5 n16:271B49D6-363D-11E5-9242-09173F13E4C5 n16:271B49D7-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 Mar;30(3):513-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18405789 # Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 Mar;30(3):499-512. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18405788 # FDA label # Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22686547
n3:group
approved
n3:halfLife
Terminal half-life = 21 hours
n3:indication
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
owl:sameAs
n10:DB06203
dcterms:title
Alogliptin
adms:identifier
n12:72323 n14:64764-250-30 n15:Alogliptin n17:DB06203 n18:D06553
n3:mechanismOfAction
Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.
n3:patent
n5:6150383 n5:6211205 n5:7807689 n5:7459428 n5:8288539 n5:6303640 n5:8173663 n5:6303661 n5:6890898 n5:7078381 n5:6329404
n3:routeOfElimination
Renal excretion (76%) and feces (13%). 60% to 71% of the dose is excreted as unchanged drug in the urine.
n3:synonym
SYR-322 Alogliptinum Alogliptina Alogliptine
n3:toxicity
Common adverse reactions (reported in ≥4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection.
n3:volumeOfDistribution
Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.
n7:hasAHFSCode
n8:68-20-05
n3:mixture
n6:271B49D4-363D-11E5-9242-09173F13E4C5 n6:271B49D5-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Alogliptin is 20% bound to plasma proteins.
n3:salt
n3:synthesisReference
Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura, "SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE." U.S. Patent US20100092551, issued April 15, 2010.
foaf:page
n20:patient-images-side-effects.htm n21:alogliptin.html
n3:IUPAC-Name
n4:271B49E0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B49E6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B49E5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B49E2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B49E3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B49E4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B49DE-363D-11E5-9242-09173F13E4C5 n4:271B49F5-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B49DC-363D-11E5-9242-09173F13E4C5 n4:271B49DF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B49DD-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n13:A10BH04
n3:H-Bond-Acceptor-Count
n4:271B49EC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B49ED-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B49E7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B49E8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B49EA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B49E9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B49EB-363D-11E5-9242-09173F13E4C5
n3:absorption
The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
850649-61-5
n3:category
n3:clearance
Renal clearance = 9.6 L/h (this value indicates some active renal tubular secretion); Systemic clearance = 14.0 L/h.
n3:Bioavailability
n4:271B49F1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B49F3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B49F4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B49F0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B49EF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B49F2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B49E1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B49EE-363D-11E5-9242-09173F13E4C5